Shanghai Medicilon Inc.

  A time to sow, a time to grow, and a time to reap.  The same is true for the biopharmaceutical industry.  With years of continuous policy and capital support, the innovation capabilities of China’s biopharmaceutical industry have absorbed nutrients for growth, and have accumulated rich experience in emerging fields such as antibodies, ADCs, PROTACs, and CGT therapies.  The generational gap with overseas pharmaceutical companies has gradually been eliminated, and we have the power to compete with the world’s top pharmaceutical companies on an equal footing.  This force drives the gears of the fate of innovative drugs from turning quietly to accelerating! At present, innovative drug research and development is deeply involved in homogeneity, and going overseas has undoubtedly become a necessary option for innovative pharmaceutical companies to seize opportunities.  The development of innovative drugs in China is ushering in an unpre...

  Medicilon’s   IND application service platform   has an in-depth understanding of the regulatory and policy environment of China and the United States and its technical requirements for chemical drugs. It can provide domestic customers with CFDA IND declaration and USFDA IND/ANDA declaration services; it can provide foreign customers with CFDA IND /ANDA declaration service. The service targets of Medicilon’s  IND  application platform include not only clients who do a complete set of preclinical research on Medicilon, but also pharmaceutical industry counterparts who require separate registration and declaration. The details are as follows: Medicilon IND Application Service: ◇ Preparation and submission of CFDA IND documents for domestic customers; ◇ Submission of USFDA IND/ANDA documents as an agent for domestic customers; ◇ Submission of CFDA IND/ANDA documents as an agent for foreign clients; ◇ Provide project management services (limited to clients who pro...